Investors Overview
We’re Delivery the Promise of Healthier Lives.
Our Company
Corporate Profile
CURE has an FDA-registered, cGMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform which includes CUREfilm®, one of the most advanced oral thin films on the market today; CUREpods™ a novel chewable delivery system and other more traditional dose forms that use advanced encapsulation technology. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE also holds the NSF® cGMP certification for manufacturing dietary supplements.
CURE’s clinical pipeline includes CUREfilm® Blue (sildenafil to treat erectile dysfunction), and CUREfilm® Canna (THC and CBD) each designed to optimize the pharmacokinetic profile of the medicine.
CURE partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets.
Cure Pharmaceutical Corporation was founded in July 2011 and is a wholly-owned subsidiary of Cure Pharmaceutical Holding Corp, a public company.
Stock Today
Headquarters
CURE Pharmaceutical
1620 Beacon Place
Oxnard, CA 93033
Phone:
Fax:
We are positioned to advance numerous therapeutic categories, including pharmaceutical cannabis.
Cure Pharmaceutical
Our Investor Presentation
Media
Recent Videos
CURE Pharmaceutical Investor
Video Webcast | Dec. 17 2020
CBD, Cannabis and the Cannabiz
In the news
Press Releases
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials for Erectile Dysfunction Product CUREfilm Blue™
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a technology focused, vertically integrated specialty pharmaceutical company, announced today successful results from its initial Pharmacokinetics (PK)/bioequivalence studies....
CURE Pharmaceutical to Present at the 2021 Sequire Cannabis Conference on Tuesday, April 20, at 2 p.m. EDT/11 a.m. PDT
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that Rob Davidson, CURE's Chief Executive Officer, and Nancy Duitch, CEO of subsidiary Sera Labs and Chief Strategic...
Nicole Kidman, Sera Labs Strategic Business Partner/Global Brand Ambassador and Nancy Duitch, Sera Labs Founder/CEO Headline Collision 2021
LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today that Academy Award, Golden Globe and Emmy Award-winning actor/producer/entrepreneur Nicole Kidman and Sera Labs CEO/CURE Pharmaceutical Chief...
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million on a Pro Forma Basis in 2020
Fiscal Year 2020 Highlights: Generated dramatic growth in total and pro forma revenue Released positive clinical data on its patented drug delivery technology and received new certifications at its research facility Acquired and expanded consumer wellness subsidiary...
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds...
CURE Pharmaceutical Announces Addition of Two New Clinical Development Programs Targeting Anti-Seizure and Antiviral Applications
OXNARD, Calif. - CURE Pharmaceutical Holding Corp. ("CURE" or the "Company") (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched two new clinical development programs and added new corresponding...
Management Team
Board of Directors
Robert Davidson
Chief Executive Officer, Director
Michael Redard
Chief Financial Officer
Nancy Duitch
Chief Strategic Officer and Director; CEO of Wholly owned subsidiary, The Sera Labs
Vered Gigi
Chief Scientific Officer
Mark Udell
Chief Accounting Officer
Jonathan Berlent
Chief Business Officer
Donna Hudson
Vice President of Quality and Compliance Systems
Ruben King-Shaw Jr.
Chairman of the Board
Robert Davidson
Chief Executive Officer, Director
Nancy Duitch
Chief Strategic Officer and Director, CEO of Wholly owned subsidiary, The Sera Labs.
Lauren Chung, Ph.D
Director
Anya Goldin
Director
Joshua Held
Director
Gene Salkind, MD
Director
William Yuan
Chairman Emeritus
Key Contacts
Corporate Counsel
K&L Gates
10100 Santa Monica Blvd., 8th Fl.
Los Angeles, CA 90067